Institutional Ownership Xtl Biopharmaceuticals LTD (XTLB)
This table provides information about the institutional ownership of Xtl Biopharmaceuticals LTD (XTLB). We have compiled data on the 6 institutions that hold shares in the stock, with a total of 451,946 shares, which have been reported (via 13F filing form) to have a value of $1.14 Million.
| Holding | Report Date | shares Held | Holding Value (Reported) | Last Trade | Trade History |
|---|---|---|---|---|---|
|
Noked Capital LTD
Tel Aviv, L3 |
Nov 14, 2022 Q3 2022 |
198,888
shares
|
$509,153
0.02% of portfolio
|
Q3 2019
Reduced -0.0%
|
|
|
Noked Israel LTD
Ramat Hasharon, L3 |
Aug 14, 2024 Q2 2024 |
198,888
shares
|
$509,153
0.13% of portfolio
|
Q3 2019
Reduced -0.0%
|
|
|
Morgan Stanley
New York, NY |
Aug 14, 2024 Q2 2024 |
33,151
shares
|
$84,866
0.0% of portfolio
|
Q1 2024
Reduced 1.51%
|
|
|
Ken Griffin
Citadel Advisors LLC | Chicago, Il
|
Aug 14, 2024 Q2 2024 |
15,435
shares
|
$39,513
0.0% of portfolio
|
Q2 2024
Added 13.23%
|
|
|
Rhumbline Advisers
Boston, MA |
Aug 01, 2024 Q2 2024 |
5,584
shares
|
$14,295
0.0% of portfolio
|
Q2 2024
New holding
|
|
|
Concourse Financial Group Securities, Inc.
Birmingham, AL |
Jul 23, 2024 Q2 2024 |
0
shares
|
$0
0.0% of portfolio
|
Q2 2024
New holding
|